Loading...
Market
Will Meiji Seika Pharma distribute the updated mRNA COVID-19 vaccine in Japan by end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Meiji Seika Pharma or Japan's Ministry of Health, Labor and Welfare
Story
Japan Approves CSL and Arcturus Therapeutics' Updated mRNA COVID-19 Vaccine for JN.1 Strain, Distributed by Meiji Seika Pharma
Sep 13, 2024, 12:04 PM
Japan's Ministry of Health, Labor and Welfare has approved CSL and Arcturus Therapeutics' updated self-amplifying mRNA COVID-19 vaccine for protection against the JN.1 strain. The vaccine will be distributed in Japan by Meiji Seika Pharma. This approval marks a significant step in Japan's efforts to combat the ongoing pandemic, leveraging advanced mRNA technology to enhance immunity against emerging strains. CSL and Meiji Seika Pharma are key players in this initiative.
View original story
Similar markets
Yes • 50%
No • 50%
Continued use without changes • 25%
Usage restrictions for certain age groups • 25%
Temporary suspension • 25%
Permanent ban • 25%
New regulations on mRNA vaccines • 25%
Public health advisory • 25%
No action taken • 25%
Further studies commissioned • 25%
Cancer immunotherapy • 25%
Influenza vaccine • 25%
HIV vaccine • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
United States • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
